Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sorafenib 400mg twice daily + intravenous infusion ofVit K1

Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month

DRUG

Sorafenib 400 mg twice daily + Intravenousinfusion of placebo

Sorafenib 400 mg twice daily + Intravenousinfusion ofplacebo daily for 6 days, followed by oral placebo twice daily x 3month

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences, New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT02259647 - Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter